Zynex (NASDAQ:ZYXI) Posts Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Zynex (NASDAQ:ZYXI) posted its quarterly earnings results on Thursday. The company reported $0.07 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.01, Briefing.com reports. The company had revenue of $49.97 million for the quarter, compared to the consensus estimate of $50.83 million. Zynex had a return on equity of 14.15% and a net margin of 3.12%. The firm’s quarterly revenue was up .1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.10 EPS.

Zynex Stock Up 4.4 %

ZYXI traded up $0.38 during trading on Friday, hitting $8.97. 140,066 shares of the company’s stock traded hands, compared to its average volume of 173,291. The company’s 50 day simple moving average is $7.96 and its two-hundred day simple moving average is $9.23. The company has a current ratio of 4.06, a quick ratio of 3.22 and a debt-to-equity ratio of 1.79. Zynex has a 12-month low of $7.04 and a 12-month high of $13.77. The stock has a market capitalization of $284.71 million, a price-to-earnings ratio of 51.72 and a beta of 0.54.

Analysts Set New Price Targets

Several analysts recently weighed in on ZYXI shares. Royal Bank of Canada cut their price target on Zynex from $12.00 to $11.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. HC Wainwright upped their price target on Zynex from $16.00 to $17.00 and gave the stock a “buy” rating in a research note on Friday.

Insider Buying and Selling at Zynex

In other Zynex news, Director Joshua R. Disbrow bought 7,000 shares of the business’s stock in a transaction on Monday, July 29th. The shares were acquired at an average cost of $8.32 per share, for a total transaction of $58,240.00. Following the purchase, the director now owns 72,000 shares in the company, valued at approximately $599,040. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Zynex news, Director Joshua R. Disbrow bought 7,000 shares of the business’s stock in a transaction on Monday, July 29th. The shares were acquired at an average cost of $8.32 per share, for a total transaction of $58,240.00. Following the purchase, the director now owns 72,000 shares in the company, valued at approximately $599,040. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Anna Lucsok sold 8,083 shares of the stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $8.03, for a total value of $64,906.49. Following the sale, the chief operating officer now owns 16,980 shares in the company, valued at approximately $136,349.40. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 52.13% of the company’s stock.

About Zynex

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.